AzTrials
AzTrials

ObesityNCT01806493

Fat Mass Estimation in Overweight and Obesity

An observational study of Obesity, run by University of Roma La Sapienza at 1 site in Italy.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The prevalence of individuals who are classified as overweight or obese is increasing all over the world and it represents a primary health concern due to the relationship between obesity and a number of diseases, disabilities, comorbidities, and mortality. Read more about this study

Who is it for?
Ages 20 to 45 years
Conditions the study is for
Obesity
How many people
103 participants
Where
1 siteItaly
Study dates
Mar 2011to Dec 2011
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 45 years
  • All sexes
  • No healthy volunteers
  • Adult

Study population: Healthy males and females aged from 25 to 45 years, with a BMI greater than 25 kg/m2 and less than 35 kg/m2, were eligible for the study.

Who may be able to join

  • Healthy males and females aged from 25 to 45 years, with a BMI greater than 25 kg/m2 and less than 35 kg/m2, were eligible for the study.

Who cannot join

  • No exclusion criteria

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • Villa delle Querce Rehabilitation Institute

    Nemi, Italy, 00040

Other trials in Italy

About this study

Official title: Body Composition Evaluation in Overweight and Obesity

The prevalence of individuals who are classified as overweight or obese is increasing all over the world and it represents a primary health concern due to the relationship between obesity and a number of diseases, disabilities, comorbidities, and mortality. The definition of obesity should consider not only the increase of body weight but more precisely the increase in body fat mass. However, body composition evaluation is rarely performed in overweight and obese subjects and the diagnosis is almost always achieved just considering body mass index (BMI). In fact, whereas BMI can be considered an important tool in epidemiological surveys, different papers stated the limitations of the use of BMI in single individuals.

Aim: to assess the determinants of body composition in a population of overweight and obese subjects and to propose a different model of estimation of fat mass (FM) in these subjects when more reliable equipments for the evaluation of body composition are not available.

Methods: in 103 overweight or obese subjects ( 74 women, aged 41.5±10 years, and 29 men, aged 43.8±8 years); a multidimensional evaluation was performed including the assessment of body composition using Dual Energy X-Ray Absorptiometry (DXA), anthropometry, bioimpedance analysis (BIA) and biochemical parameters (total cholesterol, triacylglycerol, HDL- and LDL- cholesterol, free fatty acids and glycerol, glucose, insulin, C-reactive protein, plasma acylated and unacetylated ghrelin, adiponectin and leptin serum levels).

Read the detailed description

Participants This study was based on the baseline data from a randomised controlled trial aimed at the evaluation of the effects of 2- month consumption of a combination of bioactive food ingredients on changes in body composition, satiety control, thermogenesis, serum markers of lipolysis .

The study was performed under the approval of the Ethics Committee of the Department of Internal Medicine and Medical Therapy at University of Pavia. The informed consent to the study was obtained by all the participants or their legal representatives. Healthy males and females aged from 25 to 45 years, with a BMI greater than 25 kg/m2 and less than 35 kg/m2, were eligible for the study. All subjects underwent physical examination, anthropometric assessment and routine laboratory tests. The complete medical history was collected for all the subjects. Individuals who were pregnant or lactating, or had any disease potentially affecting body composition and laboratory evaluation were excluded from the study, especially severe hepatic or renal disease, unstable cardiovascular disease, uncontrolled hypertension, active cancer or surgery for weight loss were the main exclusion criteria.

Multidimensional evaluation After a 12- hour fasting, and abstinence from water since midnight, the subjects arrived at around 8:00 a.m., using motorised transportation, at the Endocrinology and Clinical Nutrition Unit of the University of Pavia (Italy) and at the Dietetic and Metabolic Unit, "Villa delle Querce" Clinical Rehabilitation Institute in Rome (Italy).

Blood sampling for routine blood analysis and for the measurements of leptin, adiponectin, ghrelin, insulin, glycerol, free fatty acid levels, as well as the assessment of body composition by dual energy X-ray absorptiometry (DXA) and anthropometry were performed in the fasting state at baseline.

Body composition was measured using DXA (Lunar Prodigy DXA, General Electric Medical Systems, Wisconsin). The in vivo coefficients of variation were 4.2% and 0.48% for fat and lean mass, respectively. Central fat, defined as the approximation of the visceral fat, was assessed with DXA, measuring the fat percentage corresponding to an ideal rectangle defined from the upper edge of the second lumbar vertebra to the lower edge of the fourth lumbar vertebra. The vertical sides of this area were the continuation of the lateral sides of the rib cage . All measurements for each parameter were gathered by the same investigator.

The following anthropometric measurements were performed in all subjects:

body weight and height; biceps (BSF), triceps (TSF), suprailiac (SISF), and subscapular (SSSF) skinfold thicknesses, waist circumference (W), hip circumference (H), arm circumference (AC) and calf circumference (CC) In order to avoid the inter- assessor variability, anthropometric variables were measured by a unique investigator following a standardized technique .

Using the abovementioned anthropometric parameters, the following variables were calculated:

Body mass index (BMI): weight (kg) / height2 (m2) Waist to hip ratio (WHR) arm muscle area arm fat area muscle arm circumference Bioimpedance analysis (BIA): whole-body impedance vector components, resistance (R) and reactance (Xc), were measured with a single-frequency 50- KHz analyzer from AKERN Bioresearch Italy). Measurements were obtained following standardized procedures . The external calibration of the instrument was checked with a calibration circuit of known impedance value. Estimations of fat-free mass (FFM) and FM by BIA were obtained using gender- specific, BIA prediction equations recently developed by Sun et al in a large population that included extremes of BMI values. The fat mass index (FMI) was calculated through the normalisation of FM, obtained by the BIA, for height: FMI = FM (kg)/ height (m)2.

Biochemical analyses

Subjects were instructed to fast over 12 hours, and to refrain from any form of exercise for 48 hours, before blood collection. Female subjects were tested during the early follicular phase of their menstrual cycles (days 3-10). Fasting venous blood samples were drawn between 08.00 and 10.00 a.m.. Blood collection and handling were carried out under strictly standardized conditions and clinical chemistry parameters were detected with dedicated commercial kits. In particular total cholesterol, triacylglycerol, HDL- and LDL- cholesterol, free fatty acid (FFA), glycerol, glucose, insulin, C- reactive protein (CRP), plasma acylated and unacetylated ghrelin, adiponectin and leptin serum levels were measured. Leptin/ adiponectin ratio (LAR) was calculated. Insulin resistance was evaluated using the Homeostasis Model Assessment (HOMA) and Quantitative Insulin sensitivity Check Index (QUICKI) using the following formulas:

HOMA-Insulin Resistance = [(fasting insulin, mcU/ml) x (plasma glucose, mmol/l)]/22.5 QUICKI = 1/ [log (glucose, mg/dl) + log (insulin, µU/ml)] Statistical analysis Data were described as mean and standard deviation (SD) if continuous and as percentage if categorical.

We considered FM from DXA as the outcome variable and all the anthropometric, bioimpedance and laboratory data as potential explicative variables.

The predictive value of BMI and FM from BIA were compared to the FM from DXA (overall predictive value, sensibility, specificity, positive and negative predictive values). Therefore we considered the following cut-off values for the definition of obesity :

FM ≥ 25 % for men and ≥ 35 % for women (at DXA and BIA) BMI ≥ 30 kg/m2 6 The variance analysis and the Student t-test were used to assess the significance of differences in the averages; the χ2 to compare the frequencies observed with those expected; the Pearson's to evaluate the correlation existing between two continuous variables.

Variables univariately proven correlated with the outcome variable were entered a pool of potential contributors in multiple regression analysis.

We estimated models using a forward likelihood stepwise method (cut-off probability for entry: 0.05). With each added variable the discriminant function was recalculated and any variable that no longer met the significance level was removed from the equation (cut-off probability for removal: 0.1).

Some variables with similar biological significance were excluded from the logistic analysis, in order to avoid the confounding effect of collinearity (verified with Pearson's r, t-test or χ2). The best fitting model was chosen according to the value of the correlation coefficients R2, (comparing the explained variance of the model's predictions with the total variance of the data), the adjusted R2 (R2 adj), considering a correction for inclusion of variables.

We considered a significance level equal to a 5% probability of error. Data were analysed using the SPSS for Windows 10.0 (SPSS Inc 1989-1999) and the Win Episcope 2.0 [Wageningen University (N), University of Edinburgh (GB)] statistical software packages.

Conditions
Obesity
Keywords
body composition, obesity
Medical subject headings
Obesity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT01806493
Study groupRoleWhat they receive
obese subjectsOne hundred and three overweight or obese subjects were included in the study: 74 women (aged 41.5±10 years) and 29 men (aged 43.8±8 years);

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. body composition

    The purpose of this study is to verify the determinants of body composition in a population of overweight and obese subjects and to propose a different model of estimation of FM of these subjects when reliable equipments for the evaluation of body composition are not available. Body composition will be measured through anthropometry (skinfold thickness), bioimpedance analysis and DXA.

    Measured: one month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Mar 2013 (estimated)
  2. Study startMar 2011
  3. Primary completionDec 2011
  4. Study completionDec 2011

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
103 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01806493
Sponsor's protocol ID
Fasting
Status last verified
Mar 2013
First submitted
28 Feb 2013
Last updated
7 Mar 2013
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Obesity, run by University of Roma La Sapienza at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Mar 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

body composition (time frame: one month). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Mar 2013.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Fat Mass Estimation in Overweight and Obesity | AzTrials